User:Mr. Ibrahem/Floxuridine

Mr. Ibrahem/Floxuridine

Clinical data
Synonyms	5-fluorodeoxyuridine
AHFS/Drugs.com	Monograph
MedlinePlus	a682006
Pregnancy category
Routes of administration	Intra-arterial
Drug class	Antimetabolite
Identifiers
IUPAC name 5-Fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione
Chemical and physical data
Formula	C9H11FN2O5
Molar mass	246.19 g·mol−1
3D model (JSmol)	Interactive image
Melting point	150.5 °C (302.9 °F)
SMILES FC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO
InChI InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1 Y Key:ODKNJVUHOIMIIZ-RRKCRQDMSA-N Y
(verify)

Floxuridine is a medication used to treat liver cancer and gastrointestinal adenocarcinoma or colorectal cancer that has spread to the liver. It is given by gradual injection into an artery supplying the cancer.

Common side effects include bone marrow suppression, tiredness, headache, dizziness, trouble sleeping, numbness, abdominal pain, constipation, diarrhea, heart burn, nausea, mouth inflammation, and rash. Other side effects may include liver problems. Due to the severity of side effects people are generally admitted to hospital during initial treatment. It is an antimetabolite, specifically a pyrimidine analog.

Floxuridine was approved for medical use in the United States in 1970. It is available as a generic medication. In the United States 500 mg did costs about 130 USD; though the only manufacturer stopped making the medication in 2019.